Company intelligence / Profile preview

Novelwise Pharmaceutical Corporation

San Diego, California, United Statesnovelwisepharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

NBM-BMX received USFDA approval on January 4th, 2023 to proceed in Phase Ib/II clinical trials for newly diagnosed glioblastoma multiforme (GBM). The company also has a product called SugarBless for blood sugar control using prenylflavanone compounds.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculesPrenylflavanone compounds
Industry: Biotech

Drug pipeline

2 assets

NBM-BMX

Phase 2

Indications: Glioblastoma multiforme

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Novelwise Pharmaceutical Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novelwise Pharmaceutical Corporation.

Explore the full profile